drugset
Drugs / Staphylococcus aureus vaccine
last change Apr 2022 re-read 3 minutes ago

Staphylococcus aureus vaccine

also known as recombinant five-antigen Staphylococcus aureus vaccine · rFSAV

Vaccine

Developed for
staphylococcus aureus infection
Investigated by
Chengdu Olymvax Biopharmaceuticals Inc. · Jiangsu Province Centers for Disease Control and Prevention · Third Military Medical University

Trials 2

today NCT02804711 · Ph 1 NCT02820883 · Ph 0
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02820883 Jun → Aug 2016 staphylococcus aureus infection Jiangsu Province Centers for Disease Control and Prevention Completed No outcome recorded
Phase 11 trial
Phase 1 NCT02804711 Sep 2016 → Jul 2017 staphylococcus aureus infection Jiangsu Province Centers for Disease Control and Prevention Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Staphylococcus aureus vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02820883 ↗
1

NCT02804711 ↗
Known as recombinant five-antigen Staphylococcus aureus vaccine “recombinant five-antigen Staphylococcus aureus vaccine (rFSAV)” PMID 35473663 ↗ Apr 2022
Known as rFSAV “recombinant five-antigen Staphylococcus aureus vaccine (rFSAV)” PMID 35473663 ↗ Apr 2022
Modality Vaccine “recombinant five-antigen Staphylococcus aureus vaccine (rFSAV)” PMID 35473663 ↗ Apr 2022